Why Analysts See Glaukos (GKOS) Story Shifting As iDose Repeat Dosing Takes Center Stage

Simply Wall St

Thu, February 19, 2026 at 1:36 PM GMT+9 5 min read

In this article:

GKOS

+13.47%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Analysts have fine tuned their price target framework for Glaukos, with modeled fair value per share now at about US$131.77 compared with US$132.71 previously, alongside a small adjustment to the discount rate and a slightly higher long term revenue growth assumption of roughly 27.52% versus 27.21%. These shifts are closely tied to fresh views on iDose and its repeat dosing potential, which feed into how long revenue streams could run for each patient. As you read on, pay attention to how these moving pieces are shaping the story around Glaukos so you can stay informed about future updates to the narrative.

Stay updated as the Fair Value for Glaukos shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Glaukos.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Recent research has largely been supportive, with Needham, Wells Fargo and Goldman Sachs all lifting their Glaukos price targets. This signals constructive views on the company’s execution and commercial trajectory.

Needham’s David Saxon raised his target to US$127 from US$125 after Q4 revenue matched the company’s earlier preannouncement, pointing to iDose ramping and the potential for repeat administration to contribute to procedure volumes in the second half of the year and into 2027.

Wells Fargo lifted its target to US$135 from US$122 after Q4 sales aligned with the January preannouncement and management reiterated 2026 guidance. The firm highlights management’s view that Epioxa volume could eventually match Photrexa’s prior peak, which it frames as an opportunity that could exceed US$1b.

Goldman Sachs increased its target to US$138 from US$112 and points to a setup where organic growth is expected to be a key driver of relative valuation. This supports the more growth oriented part of the bullish thesis on Glaukos.

🐻 Bearish Takeaways

Even within a broadly positive research backdrop, the higher price targets from Wells Fargo, Goldman Sachs and Needham imply that some of the anticipated iDose and Epioxa contribution may already be embedded in analyst models. This can leave less room for upside surprise if execution or adoption trends fall short of expectations.

Comments around iDose re administration building into 2027 and beyond, and Epioxa potentially scaling toward a US$1b opportunity, highlight a reliance on longer term adoption and procedure trends. This can introduce risk if timing or physician uptake evolves differently than current analyst assumptions.

 






Story Continues  

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

NYSE:GKOS 1-Year Stock Price Chart

What’s in the News

Glaukos issued preliminary sales guidance for the fourth quarter and full year ended December 31, 2025, calling for total net sales of about US$143 million for Q4 and about US$507 million for the full year, with contributions outlined from U.S. Glaucoma, International Glaucoma, and Corneal Health.

The company provided net sales guidance for fiscal 2026 in the range of US$600 million to US$620 million based on current foreign exchange rates, and separately reaffirmed that same 2026 range in a later update.

Glaukos reported an impairment of intangible asset of US$112,867,000 for the fourth quarter ended December 31, 2025, a non cash item that affects reported earnings and is often watched closely by investors focused on adjustments between GAAP and non GAAP results.

The U.S. Food and Drug Administration approved a labeling supplement for iDose TR that permits re administration under a repeat treatment protocol, following Glaukos' 2025 NDA labeling supplement submission and supporting clinical data on safety and tolerability of repeat use.

How This Changes the Fair Value For Glaukos

Fair Value: The modeled fair value per share is slightly lower at about US$131.77 compared with US$132.71 previously, a move of less than US$1.

Discount Rate: The discount rate is marginally higher at 7.69% versus 7.67% previously, signaling a very small adjustment to the risk assumption in the model.

Revenue Growth: The modeled long term revenue growth rate is about 27.52% compared with 27.21% before, a modest upward tweak to top line expectations.

Net Profit Margin: The projected profit margin is now roughly 8.92% compared with 9.17% previously, indicating a small reduction in expected profitability.

Future P/E: The future P/E assumption is about 109.9x compared with 112.1x previously, a minor compression in the valuation multiple applied to forward earnings.

🔔 Never Miss an Update: Follow The Narrative

Narratives on Simply Wall St let you connect the story you believe about a company with the numbers behind it, including your view on future revenue, earnings, margins and fair value. Each Narrative links a company’s business outlook to a forecast and a fair value, then tracks how that stacks up against the share price. Narratives live in the Community page, are easy to follow, and automatically refresh when new information like news or earnings comes in so you can decide if fair value and price are still aligned.

If you are following Glaukos, it is worth seeing how the current community view ties the story to the latest fair value work in the original Narrative on Glaukos here, which sets out why repeat dosing and product breadth are so central to the thesis.

How iDose TR repeat dosing, payer coverage and minimally invasive procedures are shaping revenue assumptions and margin expectations in the forecast period.

Why Glaukos' pipeline in corneal health, glaucoma devices and retinal programs is used to support long term growth estimates and to reduce single product dependency in the model.

Which risks around competition, reimbursement, clinical outcomes and policy changes could challenge the Narrative and how that feeds into the fair value and P/E assumptions.

Curious how numbers become stories that shape markets? Explore Community Narratives

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include GKOS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info